Clinical Trials · NCT07607587
Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 114
- Start date
- May 2026
- Locations
- 11 sites, United States
- Primary endpoint
- Percentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo